<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01132768</url>
  </required_header>
  <id_info>
    <org_study_id>DSE-OLM-01-09</org_study_id>
    <nct_id>NCT01132768</nct_id>
  </id_info>
  <brief_title>The Confirmatory Olmesartan Plaque Regression Study</brief_title>
  <acronym>CONFIRM</acronym>
  <official_title>Effects of Angiotensin-Receptor Blockade With Olmesartan on Carotid Atherosclerosis in Patients With Hypertension: The Confirmatory Olmesartan Plaque Regression Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daiichi Sankyo Europe, GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daiichi Sankyo, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Effect of olmesartan medoxomil (20-40 mg) on plaque regression in hypertensive patients with
      carotid atherosclerosis.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Low recruitment
  </why_stopped>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in carotid plaque volume</measure>
    <time_frame>78 weeks (week 78 - week 0)</time_frame>
    <description>change in carotid plaque volume (PV) from baseline (week 0) as assessed by 3-D ultrasonography after 78 weeks of double-blind treatment with Olmesartan (OM) 20-40 mg daily compared to Atenololo (ATE) 50-100 mg daily (week 78 - week 0).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in plaque volume after 52 weeks, olmesartan versus atenolol</measure>
    <time_frame>52 weeks (week 52 - week 0)</time_frame>
    <description>change in plaque volume PV from baseline (week 0) to Week 52 on olmesartan therapy versus atenolol therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage changes of PV from baseline to Week 52 for olmesartan versus atenolol.</measure>
    <time_frame>52 weeks (week 52-week 0)</time_frame>
    <description>Determine the percentage changes of PV from baseline (week 0) to Week 52 for olmesartan versus atenolol.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage changes of PV from baseline to Week 78 for olmesartan versus atenolol.</measure>
    <time_frame>78 weeks (week 78 - week 0)</time_frame>
    <description>Determine the percentage changes of PV from baseline (Week 0) to Week 78 for olmesartan versus atenolol.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in seated diastolic blood pressure (SeDBP) from baseline to Week 52 for olmesartan versus atenolol.</measure>
    <time_frame>52 weeks (week 52 - week 0)</time_frame>
    <description>Determine the change in seated diastolic blood pressure (SeDBP) from baseline (week 0) to Week 52 for olmesartan versus atenolol.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in seated diastolic blood pressure (SeDBP) from baseline to Week 78 for olmesartan versus atenolol.</measure>
    <time_frame>78 weeks (week 78 - week 0)</time_frame>
    <description>Determine the change in seated diastolic blood pressure (SeDBP) from baseline (week 0) to Week 78 for olmesartan versus atenolol.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in seated systolic blood pressure (SeSBP) from baseline to Week 52 for olmesartan versus atenolol.</measure>
    <time_frame>52 weeks (week 52 - week 0)</time_frame>
    <description>Determine the change in seated systolic blood pressure (SeSBP) from baseline (week 0)to Week 52 for olmesartan versus atenolol.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in seated systolic blood pressure (SeSBP) from baseline to Week 78 for olmesartan versus atenolol.</measure>
    <time_frame>78 weeks (week 78 - week 0)</time_frame>
    <description>Determine the change in seated systolic blood pressure (SeSBP) from baseline (week 0) to Week 78 for olmesartan versus atenolol.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in PV from baseline to Week 52 after adjustments for changes in SeDBP from baseline.</measure>
    <time_frame>52 weeks (week 52 - week 0)</time_frame>
    <description>Determine the change in PV from baseline (week 0) to Week 52 after adjustments for changes in SeDBP from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in PV from baseline to Week 78 after adjustments for changes in SeDBP from baseline.</measure>
    <time_frame>78 weeks (Week 78 - week 0)</time_frame>
    <description>Determine the change in PV from baseline (week 0) to Week 78 after adjustments for changes in SeDBP from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in PV from baseline to Week 52 after adjustments for changes in SeSBP from baseline.</measure>
    <time_frame>52 weeks (week 52 - week 0)</time_frame>
    <description>Determine the change in PV from baseline (week 0) to Week 52 after adjustments for changes in SeSBP from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in PV from baseline to Week 78 after adjustments for changes in SeSBP from baseline.</measure>
    <time_frame>78 weeks (Week 78- week 0)</time_frame>
    <description>Determine the change in PV from baseline (week 0) to Week 78 after adjustments for changes in SeSBP from baseline.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">114</enrollment>
  <condition>Essential Hypertension</condition>
  <condition>Carotid Plaque</condition>
  <arm_group>
    <arm_group_label>Atenolol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Atenolol (ATE) 50 mg and/or 100 mg tablets, oral, once daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Olmesartan medoxomil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Olmesartan medoxomil (OM), 20 mg and/or 40 mg, oral, once daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atenolol</intervention_name>
    <description>Atenolol (ATE) 50 mg and/or 100 mg tablets, oral, once daily</description>
    <arm_group_label>Atenolol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>olmesartan medoxomil</intervention_name>
    <description>Olmesartan medoxomil (OM), 20 mg and/or 40 mg, oral, once daily</description>
    <arm_group_label>Olmesartan medoxomil</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female Caucasian outpatients aged &gt; 40 years.

          -  High BP defined as mean SeSBP/SeDBP ≥ 140/90 mmHg.

          -  One or more of the following additional risk factors:

          -  Smoking;

          -  Dyslipidaemia (high-density lipoprotein (HDL)-cholesterol &lt; 0.9 mmol/L or low-density
             lipoprotein (LDL)-cholesterol &gt; 2.6 mmol/L, or triglycerides &gt; 1.7 mmol/L);

          -  Left ventricular hypertrophy;

          -  Cardio-cerebrovascular events &gt; 6 months ago;

          -  Presence of target organ damage.

          -  Non-calcified (not marked shadowing) plaque in the CC artery, in the internal carotid
             artery or the carotid bulb with a PV ≥ 0.040 cm³ (≥ 40 µL) according to the
             measurements of EUTARC.

        Exclusion Criteria:

          -  Secondary or high grade hypertension including grade III hypertension (SeSBP of &gt; 180
             mmHg or SeDBP of &gt; 105 mmHg).

          -  Stroke, myocardial infarction within the previous 6 months.

          -  Interventional or surgical vascular treatment within the previous 3 months.

          -  Presence of significant narrowing of the aortic or bicuspid valve and severe
             obstruction of cardiac outflow (hypertrophic cardiomyopathy).

          -  Symptomatic heart failure.

          -  Diabetes.

          -  Chronic obstructive pulmonary disease (COPD) or asthma.

          -  Claudication intermittens stage II b or higher.

          -  Clinical evidence of severe renal disease [including renovascular occlusive disease,
             nephrectomy and/or renal transplant, creatinine clearance of &lt; 30 mL/min,
             macroalbuminuria (&gt; 300 mg albumin/24 hours or 300 µg albumin/mg creatinine)].

          -  Treatment with angiotensin converting enzyme (ACE)-inhibitors or angiotensin-receptor
             blockers (ARBs) during last 3 months.

          -  Start of treatment with a lipid-lowering agent or modification of dosage within last 3
             months.

          -  Electrocardiographic (ECG) evidence of 2nd or 3rd degree atrioventricular (AV) block,
             atrial fibrillation, cardiac arrhythmia (requiring therapy) or bradycardia (&lt; 50
             beats/min at rest).

          -  Known intolerance to study drugs.

          -  Impaired liver function tests suggesting severe liver disorder.

          -  Any life threatening disease.

          -  Duplex sonographically determined stenosis of the common or internal carotid artery &gt;
             75%.

          -  Plaque with marked shadowing from calcification.

          -  Target plaques in CC artery extending into both internal and external arteries.

          -  Pregnant or lactating female subjects.

          -  Female subjects of childbearing potential without adequate contraception:
             intra-uterine devices, hormonal contraceptives, either oral, depot, patch or
             injectable and double barrier methods such as condoms or diaphragms with spermicidal
             gel or foam. If a female becomes pregnant during the trial, she has to be withdrawn
             immediately (see section 9.4).

          -  Subject is currently enrolled in or has not yet completed at least 30 days since
             ending another investigational device or drug study or is receiving other
             investigational agents.

          -  Subject has previously entered this study.

          -  Subjects who have received ATE within 30 days prior to entering the active treatment
             phase.

          -  Subjects who are unwilling or unable to provide informed consent or to participate
             satisfactorily for the entire trial period.

          -  Subjects with history of alcohol and or drug abuse.

          -  Subjects with known malabsorption syndrome.

          -  Subjects who had donated or lost 450 mL or more blood during the last three months
             before Screening.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Klaus O Stumpe, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre of Preventative Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Sesto Fiorentino</city>
        <zip>50019</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 26, 2010</study_first_submitted>
  <study_first_submitted_qc>May 26, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 28, 2010</study_first_posted>
  <last_update_submitted>March 30, 2012</last_update_submitted>
  <last_update_submitted_qc>March 30, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 2, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Olmesartan</mesh_term>
    <mesh_term>Olmesartan Medoxomil</mesh_term>
    <mesh_term>Atenolol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

